Bristol-Myers expands alliance with Immuneering Corporation Bristol-Myers Squibb has entered into an agreement to expand its existing relationship with Immuneering Corporation for the use of Immuneering's proprietary computational biology methods to identify biological insights that may facilitate discovery and development of medicines. Terms of agreement were not disclosed.
News For BMY From The Last 14 Days
Check below for free stories on BMY the last two weeks.
Teva launches generic Baraclude in U.S. Teva (TEVA) announces the launch of the generic equivalent to Baraclude tablets in the U.S. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Baraclude is marketed by Bristol-Myers Squibb (BMY).